Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 16/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.51 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.51 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31696441 | 1.00 | KCNT1 (0.51) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696485 | 1.00 | KCNT1 (0.51) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696430 | 0.95 | KCNT1 (0.48) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696423 | 0.95 | KCNT1 (0.48) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696663 | 0.88 | KCNT1 (0.56) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696498 | 0.87 | KCNT1 (0.46) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696601 | 0.86 | KCNT1 (0.45) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696388 | 0.85 | KCNT1 (0.45) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL31696566 | 0.84 | RAF1 (0.41) | — | |
| SCHEMBL31696587 | 0.84 | PDE4B (0.40) | KCNT1KCNQ1KCNH2CACNA1CSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | KCNT1 1/4885KCNQ1 4/4885KCNH2 25/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | KCNT1 1/4885KCNQ1 9/4885KCNH2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.